VivoSeq
Neurology

Huntington Disease

34

Pipeline Programs↗

6

Active Trials↗

22

Companies Involved↗

Huntington disease is a moderately active landscape with 34 programs across 22 companies. The most active players are Siena Biotech S.p.A., Santhera Pharmaceuticals, Roche. 12 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

11/100

Mech. Concentration

6/100

Completion Rate

85/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Siena Biotech S.p.A.

1 program

Phase 1S

Santhera Pharmaceuticals

1 program

Phase 1Roche logo

Roche

1 program

Phase 2E

EIP Pharma Inc

1 program

Phase 2P

Prana Biotechnology Limited

1 program

Phase 2Neurocrine Biosciences logo

Neurocrine Biosciences

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

31 of 32 classified programs — the dominant modality here.

3%ALL OTHERSProtein / enzyme13%

Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 91% of 35 pipeline programs.

Analysis

Trial Status

19

clinical trials

Completed11 · 58%
Recruiting3 · 16%
Terminated2 · 11%
Active, not recruiting2 · 11%
Enrolling by invitation1 · 5%

Clinical Trials

Trial Activity

19 trials

A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
Recruiting·SSkyhawk Therapeutics, Inc.·Preclinical·NCT07378644·400 enrolled
A Randomized, Placebo-controlled, Double-blind Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Recruiting·Novartis logoNovartis·Phase 3·NCT07326709·770 enrolled
Frequency of Selected Single Nucleotide Polymorphisms in Phase With the Mutant and Wild-Type HTT Alleles in Huntington Disease Gene Expansion Carriers
Recruiting·Roche logoRoche·N/A·NCT06667414·600 enrolled
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
Active, not recruiting·Neurocrine Biosciences logoNeurocrine Biosciences·Phase 3·NCT04400331·154 enrolled
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
Active, not recruiting·VVanderbilt University Medical Center·Phase 2/3·NCT04713982·30 enrolled
Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada
Enrolling by invitation·Neurocrine Biosciences logoNeurocrine Biosciences·Phase 3·NCT06312189·7 enrolled
Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
Completed·PPrilenia·Phase 2·NCT01306929·134 enrolled
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
Completed·PPrana Biotechnology Limited·Phase 2·NCT01590888·109 enrolled
PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD
Completed·PPrilenia·Phase 3·NCT04556656·499 enrolled
Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease
Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 2·NCT01882062·10 enrolled
A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease
Completed·MMedivation, Inc.·Phase 3·NCT00920946·403 enrolled
A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease
Completed·UUniversity of British Columbia·Phase 2·NCT01458470·19 enrolled
Alternatives for Reducing Chorea in Huntington Disease
Completed·AAuspex Pharmaceuticals, Inc.·Phase 3·NCT01897896·119 enrolled
Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00632645·180 enrolled
A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease
Completed·SSiena Biotech S.p.A.·Phase 1·NCT01485965·26 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)